Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial

BACKGROUND: Systemic sclerosis (SSc) is an autoimmune, connective tissue disease characterized by vasculopathy and fibrosis of the skin and internal organs. METHODS: We randomized 15 participants with early diffuse cutaneous SSc to tofacitinib 5 mg twice a day or matching placebo in a phase I/II dou...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanna, Dinesh, Padilla, Cristina, Tsoi, Lam C., Nagaraja, Vivek, Khanna, Puja P., Tabib, Tracy, Kahlenberg, J. Michelle, Young, Amber, Huang, Suiyuan, Gudjonsson, Johann E., Fox, David A., Lafyatis, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536259/
https://www.ncbi.nlm.nih.gov/pubmed/35943798
http://dx.doi.org/10.1172/jci.insight.159566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536259/
https://www.ncbi.nlm.nih.gov/pubmed/35943798
http://dx.doi.org/10.1172/jci.insight.159566

Ejemplares similares